Suboptimal response to or failure of imatinib treatment for chronic myeloid leukemia: what is the optimal strategy?

ABSTRACT: Treatment responses to imatinib vary among patients with chronic myeloid leukemia (CML), and definitions of treatment failure and suboptimal response have been published. This article discusses monitoring and treatment of patients with CML after failure of or suboptimal response to imatinib therapy. We reviewed articles listed on PubMed from January 1, 2002, to July 31, 2008, and abstracts from the 2007 Annual Meeting of the American Society of Hematology. Search terms used were chronic myeloid/myelogenous leukemia, imatinib, and BCR-ABL. To enable early recognition of suboptimal responses, patients should be frequently monitored according to published guidelines, including cytogenetic analysis every 6 months until a complete response is achieved and molecular monitoring every 3 months fro

SUBMITTER: Jabbour E 

PROVIDER: S-EPMC2664587 | biostudies-literature | 2009 Feb

REPOSITORIES: biostudies-literature